| scholarly article | Q13442814 |
| P50 | author | Stanley B Cohen | Q91720749 |
| P2093 | author name string | Vincent Chow | |
| Robert R Labadie | |||
| Samuel H Zwillich | |||
| Bethanie Wilkinson | |||
| P2860 | cites work | Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes | Q24313200 |
| Regulation of JAK3 expression and activation in human B cells and B cell malignancies | Q24316337 | ||
| Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7 | Q24679411 | ||
| Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID | Q28241595 | ||
| Cytokines and their role in lymphoid development, differentiation and homeostasis | Q30891389 | ||
| American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. | Q34782898 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| Cells of the synovium in rheumatoid arthritis. T lymphocytes. | Q35769049 | ||
| B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? | Q36106119 | ||
| A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal | Q36200678 | ||
| Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. | Q37038783 | ||
| Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients | Q40147073 | ||
| A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. | Q44552235 | ||
| Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. | Q50779374 | ||
| Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. | Q51866375 | ||
| Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. | Q55047291 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions | Q81178481 | ||
| The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road | Q81360845 | ||
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial | Q82690898 | ||
| Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis | Q83370441 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | methotrexate | Q422232 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 143-151 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment | |
| P478 | volume | 69 |
| Q38097494 | A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis |
| Q37900647 | Current landscape for T-cell targeting in autoimmunity and transplantation |
| Q91715288 | Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism |
| Q89689218 | Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis |
| Q36010298 | DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing |
| Q34047746 | Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis |
| Q36038705 | Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis |
| Q37562464 | Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group |
| Q54312411 | Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. |
| Q37420530 | Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food |
| Q48933623 | Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis |
| Q26772850 | Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies |
| Q37926574 | JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth |
| Q43963029 | Janus kinase inhibitors |
| Q49232396 | Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study |
| Q34677487 | Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis |
| Q42713895 | Stimulation of human TRPA1 channels by clinical concentrations of the antirheumatic drug auranofin |
| Q34858352 | The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis |
| Q56852193 | Tofacitinib |
| Q38110227 | Tofacitinib: a review of its use in adult patients with rheumatoid arthritis |
| Q35092982 | Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate |
| Q38604390 | Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib |
Search more.